In response to recent First Amendment-related court decisions addressing the extent to which the government can control manufacturer communications regarding off-label uses of medical products, the FDA decided to solicit input. A public hearing on the topic was held November 9-10, 2016.
If you didn’t attend, you may not fully understand the public health and constitutional issues involved and how the hearing could influence the FDA’s next steps.
Watch now to understand what took place during the hearing and the implications for 2017, including: